Keytruda gains expanded US approval in skin cancer
Checkpoint inhibitor has been approved to treat locally advanced cutaneous squamous cell carcinoma
Read More
Tag: cutaneous squamous cell carcinoma
MSD’s Keytruda bags approval for new skin cancer indication
In trials Keytruda showed ‘meaningful efficacy’ with an objective response rate of 34%
Read More
EU reviews for Sanofi’s Dupixent, cemiplimab
European regulators have agreed to review Sanofi and Regeneron’s Dupixent for asthma and cemiplimab for advanced cutaneous squamous cell carcinoma.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
